POTENTIAL OF STEM CELL THERAPY AND REGENERATIVE MEDICINE FOR REVERSING LIVER DAMAGE IN NAFLD

S KHAN; K ZAMAN; P SAINANI; . SANAM; V SAINANI

doi:10.54112/bcsrj.v2024i1.1634

Authors

S KHAN Jinnah Postgraduate Medical Centre Karachi, Pakistan
K ZAMAN Jinnah Postgraduate Medical Centre Karachi, Pakistan
P SAINANI Department of Nephrology, Chiniot General Hospital, Chiniot, Pakistan
. SANAM Sindh govt hospital Saudabad Malir Karachi, Pakistan
V SAINANI Jinnah Postgraduate Medical Centre Karachi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1634

Keywords:

Non-alcoholic Fatty Liver Disease, Stem Cell Transplantation, Liver Regeneration, Liver Function Tests, Quality of Life

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a growing concern worldwide, with limited treatment options for its advanced stages, including non-alcoholic steatohepatitis (NASH) and cirrhosis. Objective: This study aims to evaluate the efficacy of stem cell therapy in reversing liver damage in patients with NAFLD. Methods: 25 patients aged 18-65, diagnosed with advanced stages of NAFLD, were enrolled in this single-arm clinical trial. Patients received a one-time infusion of autologous stem cells, and liver function, imaging, and biopsy results were monitored at baseline and 12 months post-treatment. The primary outcomes included changes in liver function tests (ALT, AST, bilirubin), liver imaging, liver biopsy, and quality of life. Results: Significant improvements were observed in liver function tests, with ALT decreasing by 40%, AST by 41%, and total bilirubin by 39% (p < 0.01 for ALT and AST, p < 0.05 for bilirubin). Liver imaging showed a 37% reduction in fat fraction and a 28% reduction in liver stiffness (p < 0.05). Liver biopsy results demonstrated a 40% improvement in fibrosis stage, with 30% of patients improving from stages 2-3 to stages 1-2. Hepatocyte regeneration showed a 400% improvement (p < 0.01). Quality of life improved by 50%, from a score of 5.2 to 7.8 (p < 0.05). Conclusions: Stem cell therapy demonstrated significant liver regeneration and functional improvement in patients with advanced NAFLD. These findings suggest that stem cell therapy may provide a promising therapeutic option for reversing liver damage in NAFLD. Larger, controlled studies are needed to confirm these results and assess stem cell therapy's long-term safety and efficacy for NAFLD.

Downloads

Download data is not yet available.

References

Kweon M, Kim JY, Jun JH, Kim GJ. Research Trends in the Efficacy of Stem Cell Therapy for Hepatic Diseases Based on MicroRNA Profiling. Int J Mol Sci. 2020 Dec 29;22(1):239. doi: 10.3390/ijms22010239. PMID: 33383629; PMCID: PMC7795580.

Liu, P., Mao, Y., Xie, Y. et al. Stem cells for liver fibrosis/cirrhosis treatment: clinical progress and therapeutic potential. Stem Cell Res Ther 13, 356 (2022). https://doi.org/10.1186/s13287-022-03041-5

Gao FQ, Zhu JQ, Feng XD. Innovative mesenchymal stem cell treatments for fatty liver disease. World J Stem Cells. 2024 Sep 26;16(9):846-853. doi: 10.4252/wjsc.v16.i9.846. PMID: 39351260; PMCID: PMC11438732.

Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516–537. doi: 10.1016/j.jhep.2023.03.017.

Huang DQ, Terrault NA, Tacke F, Gluud LL, Arrese M, Bugianesi E, Loomba R. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20:388–398. doi: 10.1038/s41575-023-00759-2.

Singal AK. Similarities and differences between non-alcoholic fatty liver disease (NAFLD) and alcohol-associated liver disease (ALD). Transl Gastroenterol Hepatol. 2021;6:1. doi: 10.21037/tgh-2019-nafld-15.

Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N, Suganuma N. Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci. 2019;76:3323 3348. doi: 10.1007/s00018-019-03125-1.

Korkida F, Stamatopoulou A, Roubelakis MG. Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease. Stem Cells Transl Med. 2024;13:107 115. doi: 10.1093/stcltm/szad082.

Zheng L, Gong H, Zhang J, Guo L, Zhai Z, Xia S, Hu Z, Chang J, Jiang Y, Huang X, Ge J, Zhang B, Yan M. Strategies to improve the therapeutic efficacy of mesenchymal stem cell-derived extracellular vesicle (MSC-EV): a promising cell-free therapy for liver disease. Front Bioeng Biotechnol. 2023;11:1322514. doi: 10.3389/fbioe.2023.1322514.

Jiang Y, Yusoff NM, Du J, Moses EJ, Lin JT. Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease. World J Stem Cells. 2024;16:760–772. doi: 10.4252/wjsc.v16.i7.760.

Sakai Y, Fukunishi S, Takamura M, Kawaguchi K, Inoue O, Usui S, Takashima S, Seki A, Asai A, Tsuchimoto Y, Nasti A, Bich Ho TT, Imai Y, Yoshimura K, Murayama T, Yamashita T, Arai K, Yamashita T, Mizukoshi E, Honda M, Wada T, Harada K, Higuchi K, Kaneko S. Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy. Regen Ther. 2021;18:97 101. doi: 10.1016/j.reth.2021.04.003.

Hu J, Li S, Zhong X, Wei Y, Sun Q, Zhong L. Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice. Heliyon. 2024;10:e25460. doi: 10.1016/j.heliyon.2024.e25460.

Watanabe T, Tsuchiya A, Takeuchi S, Nojiri S, Yoshida T, Ogawa M, Itoh M, Takamura M, Suganami T, Ogawa Y, Terai S. Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles. Regen Ther. 2020;14:252–261. doi: 10.1016/j.reth.2020.03.012.

Yang Z, Xia Q, Lu D, Yue H, Zhang J, Li Y, Zhang B, Li X, Cao M. Human mesenchymal stem cells treatment improved hepatic lesions and reversed gut microbiome disorder in non-alcoholic steatohepatitis. Aging (Albany, NY) 2020;12:21660 21673. doi: 10.18632/aging.103962.

Wang H, Zhang H, Huang B, Miao G, Yan X, Gao G, Luo Y, Chen H, Chen W, Yang L. Mesenchymal stem cells reverse highfat dietinduced nonalcoholic fatty liver disease through suppression of CD4+ T lymphocytes in mice—Mol Med Rep. 2018;17:3769–3774. doi: 10.3892/mmr.2017.8326.

Wang H, Wang D, Yang L, Wang Y, Jia J, Na D, Chen H, Luo Y, Liu C. Compact bone-derived mesenchymal stem cells attenuate nonalcoholic steatohepatitis in a mouse model by modulation of CD4 cells differentiation. Int Immunopharmacol. 2017;42:67 73. doi: 10.1016/j.intimp.2016.11.012.

Li L, Zeng X, Liu Z, Chen X, Li L, Luo R, Liu X, Zhang J, Liu J, Lu Y, Cheng J, Chen Y. Mesenchymal stromal cells protect hepatocytes from lipotoxicity through alleviation of endoplasmic reticulum stress by restoring SERCA activity. J Cell Mol Med. 2021;25:2976 2993. doi: 10.1111/jcmm.16338.

Du J, Jiang Y, Liu X, Ji X, Xu B, Zhang Y, Liu Y, Zhang T, Lin J. HGF Secreted by Menstrual Blood-Derived Endometrial Stem Cells Ameliorates Non-Alcoholic Fatty Liver Disease Through Downregulation of Hepatic Rnf186. Stem Cells. 2023;41:153–168. doi: 10.1093/stmcls/sxac091.

Bi Y, Guo X, Zhang M, Zhu K, Shi C, Fan B, Wu Y, Yang Z, Ji G. Bone marrow-derived mesenchymal stem cell improves diabetes-associated fatty liver via mouse mitochondria transformation. Stem Cell Res Ther. 2021;12:602. doi: 10.1186/s13287-021-02663-5.

Nickel S, Christ M, Schmidt S, Kosacka J, Kühne H, Roderfeld M, Longerich T, Tietze L, Bosse I, Hsu MJ, Stock P, Roeb E, Christ B. Human Mesenchymal Stromal Cells Resolve Lipid Load in High-Fat Diet-Induced Non-Alcoholic Steatohepatitis in Mice by Mitochondria Donation. Cells. 2022;11 doi: 10.3390/cells11111829.